AbbVie Quarterly Balance Sheet
NYSE: ABBVHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:01 PM ET · Delayed 15 min
AbbVie financial position
As of Jun 30, 2026, AbbVie reported total assets of $135.12 billion, down 1.5% from a year earlier against total liabilities of $141.00 billion. Shareholders' equity was negative at -$5.93 billion, meaning liabilities exceed assets; this is often the result of large share buybacks or accumulated losses. The company held $6.57 billion in cash and equivalents against $70.82 billion of debt, a net debt position of $64.25 billion.
The current ratio (current assets divided by current liabilities) was 0.81, meaning short-term obligations exceed short-term assets.
Summary generated from market data by MetaCap's automated system. Methodology
AbbVie balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 6.57B | 9.39B | 5.23B | 5.63B | 6.47B | 5.17B | 5.52B | 7.26B | 13.13B | 18.07B | 12.81B | 13.29B |
| Short-Term Investments | — | — | 28.00M | 42.00M | 0 | 1.00M | 31.00M | 28.00M | 27.00M | 2.00M | 2.00M | 3.00M |
| Receivables | 13.82B | 12.48B | 12.59B | 12.77B | 12.64B | 12.48B | 10.92B | 11.47B | 11.72B | 11.95B | 11.15B | 11.41B |
| Inventory | 5.13B | 5.05B | 4.95B | 4.94B | 4.96B | 4.53B | 4.18B | 4.45B | 4.22B | 4.25B | 4.10B | 3.98B |
| Total Current Assets | 33.67B | 33.53B | 29.06B | 28.54B | 29.26B | 27.68B | 25.58B | 27.79B | 33.82B | 38.87B | 33.00B | 33.22B |
| Property, Plant & Equipment | 5.80B | 5.69B | 5.63B | 5.48B | 5.28B | 5.24B | 5.13B | 5.14B | 5.02B | 4.98B | 4.99B | 4.93B |
| Goodwill | 35.52B | 35.57B | 35.64B | 35.63B | 35.64B | 35.28B | 34.96B | 35.30B | 33.39B | 33.43B | 32.29B | 32.09B |
| Intangible Assets | 49.14B | 50.87B | 52.64B | 54.31B | 57.03B | 58.49B | 60.07B | 66.65B | 60.24B | 62.23B | 55.61B | 58.60B |
| Long-Term Investments | 266.00M | 268.00M | 268.00M | 291.00M | 310.00M | 287.00M | 279.00M | 267.00M | 272.00M | 305.00M | 304.00M | 275.00M |
| Total Assets | 135.12B | 136.46B | 133.96B | 133.90B | 137.18B | 136.16B | 135.16B | 143.42B | 141.94B | 148.87B | 134.71B | 136.22B |
| Accounts Payable | 33.30B | 33.77B | 3.59B | 33.62B | 32.24B | 31.04B | 2.94B | 30.49B | 29.33B | 31.33B | 3.69B | 29.66B |
| Short-Term Debt | 8.34B | 8.33B | 8.55B | 5.77B | 7.52B | 5.36B | 6.80B | 12.57B | 12.59B | 10.20B | 7.19B | 5.12B |
| Total Current Liabilities | 41.64B | 42.10B | 43.29B | 39.39B | 39.77B | 36.40B | 38.75B | 43.06B | 41.91B | 41.52B | 37.84B | 34.77B |
| Long-Term Debt | 62.48B | 64.53B | 58.94B | 62.97B | 62.96B | 64.53B | 60.34B | 58.51B | 58.05B | 63.80B | 52.19B | 55.63B |
| Total Liabilities | 141.00B | 143.07B | 137.19B | 136.50B | 137.32B | 134.70B | 131.80B | 137.35B | 135.12B | 140.83B | 124.31B | 124.09B |
| Shareholders' Equity | -5.93B | -6.66B | -3.27B | -2.64B | -183.00M | 1.42B | 3.33B | 6.03B | 6.78B | 8.01B | 10.36B | 12.09B |
| Retained Earnings | -17.33B | -17.87B | -15.49B | -14.23B | -11.50B | -9.53B | -7.90B | -4.96B | -3.77B | -2.38B | -1.00B | 933.00M |
| Total Debt | 70.82B | 72.86B | 67.50B | 68.74B | 70.48B | 69.89B | 67.14B | 71.08B | 70.63B | 74.00B | 59.38B | 60.75B |
| Net Cash (Debt) | -64.25B | -63.47B | -62.24B | -63.07B | -64.01B | -64.71B | -61.59B | -63.79B | -57.48B | -55.93B | -46.57B | -47.46B |
This table shows 12 quarterly periods of AbbVie's balance sheet, from Q2 2026 back to Q3 2023, across 19 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow ABBV's reporting calendar. What is a balance sheet?